Peptides and Type 2 Diabetes: Blood Sugar Management Research

By the NorthPeptide Research Team  |  February 7, 2026

Type 2 Diabetes: Why Peptides Are Central to Current Research

Type 2 diabetes (T2D) is characterised by insulin resistance and progressive beta cell dysfunction. The pancreas initially overproduces insulin to compensate for resistance, then gradually loses the ability to keep up — leading to chronic hyperglycaemia. Unlike Type 1, the autoimmune component is absent, but the metabolic consequences are similarly severe over time: cardiovascular disease, neuropathy, nephropathy, and retinopathy.

Peptide research has become central to T2D because gut-derived peptide hormones — GLP-1, GIP, and related molecules — are natural regulators of insulin secretion, blood glucose, appetite, and body weight. Harnessing these pathways pharmacologically has proven highly effective. The GLP-1 receptor agonist class is now one of the most researched drug categories in the world.

Semaglutide: The GLP-1 Benchmark

Semaglutide is a GLP-1 receptor agonist designed with modifications to extend its half-life — allowing once-weekly dosing. In clinical trials for T2D (SUSTAIN programme), it produced average HbA1c reductions of 1.5-1.8% and significant weight loss. The LEADER and similar cardiovascular outcome trials confirmed that GLP-1 agonists reduce major adverse cardiovascular events in high-risk T2D patients.

At the research level, semaglutide has also been studied for its effects on beta cell function, insulin sensitivity, and non-alcoholic fatty liver disease (NAFLD), which frequently co-occurs with T2D.

Tirzepatide: GLP-1/GIP Dual Agonism

Tirzepatide is a once-weekly injectable that acts simultaneously on both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. The addition of GIP agonism appears to enhance insulin secretion in a glucose-dependent manner and may provide complementary benefits on adipose tissue metabolism. In SURPASS clinical trials, tirzepatide produced HbA1c reductions of up to 2.3% — greater than any previous single agent — along with substantial weight loss.

The dual receptor mechanism appears to be genuinely additive: GLP-1 primarily drives satiety and slows gastric emptying, while GIP contributes to insulin secretion and may have direct effects on fat cells. The combination achieves better glycaemic control with comparable tolerability.

Retatrutide: Triple Receptor Agonism

Retatrutide adds glucagon receptor agonism to the GLP-1/GIP combination. Glucagon is classically viewed as a counterregulatory hormone that raises blood sugar — but at the doses and context provided by co-administration with GLP-1 agonism, glucagon receptor activity appears to increase energy expenditure and drive additional weight loss. Phase 2 trials showed retatrutide produced up to 17% average weight loss over 24 weeks in T2D patients — with corresponding improvements in HbA1c and metabolic markers.

Retatrutide also showed improvements in hepatic fat content and liver enzymes — relevant given the strong T2D/NAFLD connection.

Other Peptides in T2D Research

Amylin and Cagrilintide

Amylin is a peptide co-secreted with insulin from pancreatic beta cells. It slows gastric emptying, suppresses postprandial glucagon, and reduces appetite. Pramlintide (synthetic amylin analogue) is FDA-approved as adjunct therapy in diabetes. Cagrilintide, a long-acting amylin analogue, is in clinical development combined with semaglutide — showing additive effects on weight and blood sugar.

GLP-2 and Gut Integrity

GLP-2 is co-secreted with GLP-1 from intestinal L-cells and acts on gut tissue — promoting intestinal growth, reducing permeability, and supporting nutrient absorption. While not a direct blood sugar agent, gut integrity research is relevant in T2D given the emerging gut-metabolism axis.

References